Innovent Biologics, Inc.: all 216 studies

Page 2 of 3. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.

• A Study of IBI362 9 mg in Chinese Adults With ObesityActive, not recruitingNCT06164873Phase 3
• A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye DiseaseCompletedNCT06126783Phase 3
• Safety and Tolerance Study of IBI355 in Health VolunteersCompletedNCT06110338Phase 1
• IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentCompletedNCT06049810Phase 3
• A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid TumorsCompletedNCT05991349Phase 1/2
• A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMDActive, not recruitingNCT05972473Phase 3
• A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With BiologicsCompletedNCT05970978Phase 2
• Evaluation of IBI302 Injection in nAMD or DMESuspendedNCT05961007Phase 1/2
• A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon CancerActive, not recruitingNCT05890742Phase 3
• Parsaclisib in Patients With Relapsed or Refractory Follicular LymphomaWithdrawnNCT05867030Phase 1
• The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)TerminatedNCT05849246Phase 2
• A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsCompletedNCT05815680Phase 1
• A Study of IBI311 in Subjects With Active Thyroid Eye DiseaseCompletedNCT05795621Phase 2/3
• Pharmacokinetics of IBI362 in Subjects With and Without Renal ImpairmentCompletedNCT05793450Phase 1
• Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male VolunteersCompletedNCT05792917Phase 1
• The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.CompletedNCT05774873Phase 1/2
• A Study of IBI351 in Healthy SubjectsCompletedNCT05699993Phase 1
• A Study of IBI351 in Healthy SubjectsCompletedNCT05688124Phase 1
• IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract CancerStatus unknownNCT05653180Phase 1/2
• A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque PsoriasisCompletedNCT05645627Phase 3
• A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular DegenerationCompletedNCT05639530Phase 1
• A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseCompletedNCT05628311Phase 3
• A Study of [14C]IBI351 in Healthy SubjectsCompletedNCT05626179Phase 1
• A Study of IBI362 in Participants With Obesity or OverweightCompletedNCT05607680Phase 3
• A Study of IBI362 in Participants With Type 2 DiabetesCompletedNCT05606913Phase 3
• A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous MelanomaWithdrawnNCT05572463Phase 1/2
• A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal CancerTerminatedNCT05497336Phase 1
• A Study of IBI353 (Orismilast) in Chinese Healthy AdultsCompletedNCT05490316Phase 1
• A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular EdemaCompletedNCT05489718Phase 1
• A Study of IBI311 in Healthy VolunteersCompletedNCT05480579Phase 1
• Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or LymphomaActive, not recruitingNCT05460767Phase 1
• A Study of Longer Interval of IVT IBI302 in Subjects With nAMDCompletedNCT05403749Phase 2
• A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative ColitisCompletedNCT05377580Phase 2
• Phase I Study of Sintilimab in Healthy Chinese Male SubjectsCompletedNCT05337267Phase 1
• A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or LymphomasActive, not recruitingNCT05290597Phase 1
• IBI397 or Combination Therapies in Patients With Advanced MalignanciesWithdrawnNCT05245916Phase 1
• Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345CompletedNCT05199519Phase 1
• A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid TumorsStatus unknownNCT05172856Phase 1
• A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19TerminatedNCT05172141Phase 1/2
• A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19TerminatedNCT05162365Phase 1/2
• A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid TumorTerminatedNCT05148442Phase 1
• A Phase I Study of IBI325 in Patients With Advanced Solid TumorCompletedNCT05119998Phase 1
• IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)CompletedNCT05118334Phase 1
• Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerActive, not recruitingNCT05116462Phase 3
• Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung CancerTerminatedNCT05088967Phase 1
• A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid TumorsCompletedNCT05043298Phase 1
• Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)Status unknownNCT05039658Phase 1
• A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT05026593Phase 1
• Study of Bevacizumab With Different Manufacturing Process in Healthy Male SubjectsCompletedNCT05005455Phase 1
• A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C MutationsCompletedNCT05005234Phase 1/2
• A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT05003531Phase 2
• A Study of IBI362 in Chinese Patients With Type 2 DiabetesCompletedNCT04965506Phase 2
• IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPCCompletedNCT04945421Phase 1
• Study of IBI323 in Patients With Advanced MalignanciesStatus unknownNCT04916119Phase 1
• IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.CompletedNCT04912466Phase 1
• A Study of Dose Escalation of IBI321 in Patients With Advanced Solid TumorsCompletedNCT04911894Phase 1
• A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid TumorsCompletedNCT04911881Phase 1
• A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsCompletedNCT04904913Phase 2
• A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male VolunteersCompletedNCT04868760Phase 1
• IBI188 Combination Therapy in Solid TumorsTerminatedNCT04861948Phase 1
• A Study of IBI302 in Patients With nAMDCompletedNCT04820452Phase 2
• A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic MalignancyCompletedNCT04795128Phase 1
• Clinical Study of IBI362 in Healthy Chinese Male SubjectsCompletedNCT04773977Phase 1
• A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCCompletedNCT04720716Phase 3
• A Study of IBI306 in Participants With HypercholesterolemiaCompletedNCT04709536Phase 3
• Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant TumorsStatus unknownNCT04708210Phase 1
• A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)TerminatedNCT04675983Phase 3
• A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above ChemotherapiesCompletedNCT04672928Phase 1
• A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLCCompletedNCT04672369Phase 1
• A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung CancerCompletedNCT04672356Phase 1
• A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular CarcinomaTerminatedNCT04635527Phase 1
• Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell CarcinomaTerminatedNCT04611321Phase 1/2
• Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) TrialTerminatedNCT04602065Phase 1/2
• A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based ChemotherapyCompletedNCT04590599Phase 2
• A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDSSuspendedNCT04511975Phase 1
• Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy SubjectsCompletedNCT04511624Phase 1
• Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDSSuspendedNCT04485065Phase 1
• Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid LeukemiaSuspendedNCT04485052Phase 1/2
• Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMCompletedNCT04466904Phase 1/2
• Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity SubjectsCompletedNCT04440345Phase 1/2
• A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid TumorTerminatedNCT04427774Phase 1
• Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular CarcinomaCompletedNCT04401813Phase 1
• Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD PatientsCompletedNCT04370379Phase 1
• A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant TumorsCompletedNCT04353830Phase 1
• A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced CancersCompletedNCT04338659Phase 1
• Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant TumorsCompletedNCT04328831Phase 1
• IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone LymphomaCompletedNCT04298879Phase 2
• Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial HypercholesterolemiaCompletedNCT04289285Phase 3
• The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by SurgeryTerminatedNCT04277663Phase 3
• Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR AlterationsCompletedNCT04258527Phase 1
• IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal CancerTerminatedNCT04258111Phase 2
• Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 RearrangementCompletedNCT04256980Phase 2
• Intense Monitoring Study on TyvytStatus unknownNCT04237233
• A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host DiseaseTerminatedNCT04220632Phase 1/2
• Safety and Efficacy of IBI306 in HeFH PatientsCompletedNCT04179669Phase 3
• A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC PatientsCompletedNCT04177290Phase 1
• A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid TumorCompletedNCT04162327Phase 1
• A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant TumorsStatus unknownNCT04085185Phase 1
• A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard ChemotherapyStatus unknownNCT04044222Phase 3
• A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial HypercholesterolemiaCompletedNCT04031742Phase 2/3

← Innovent Biologics, Inc. overview and focus areas